RxDoctor Payments Data

John Hong, MD

Internal Medicine · Cape May Court House, NJNPI 1871573063

Payments from drug & device makers

$214in general payments, 2019–2025

Across 5 payments — averaging $42.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mirum Pharmaceuticals, Inc.$150
  • Pfizer$18
  • Lilly USA, LLC$18
  • GSK$14
  • AstraZeneca$14

What the payments were for

  • Food & beverage$214100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Mirum Pharmaceuticals, Inc.1$150
Pfizer1$18
Lilly USA, LLC1$18
GSK1$14
AstraZeneca1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$214 in reported general payments places this provider in the 40th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$181,270
Medicare patients
292
Services billed
4,995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate32$45,243
JardianceEmpagliflozin29$41,257
OzempicSemaglutide23$35,447
MyrbetriqMirabegron32$24,583
EliquisApixaban21$24,538
FarxigaDapagliflozin Propanediol17$23,200
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$19,311
Praluent PenAlirocumab18$9,783
SynthroidLevothyroxine Sodium95$9,194
Rosuvastatin Calcium578$7,939
Metoprolol Succinate158$2,783
Duloxetine Hcl92$2,639
Carvedilol ErCarvedilol Phosphate13$2,389
Pantoprazole Sodium121$2,140
VascepaIcosapent Ethyl12$2,128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$24,53821 claims
AstraZenecaFarxiga$14$23,20017 claims
GSKTrelegy Ellipta$14$19,31121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Cape May Court House

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →